跳至主要内容
临床试验/ISRCTN38408464
ISRCTN38408464已完成未知

Pragmatic trial to assess the possibility of enhancing the effectiveness of tinnitus retraining therapy (TRT) by concomitant treatment with Ginkgo Biloba extract EGb 761® in patients with chronic tinnitus

Dr. Willmar Schwabe GmbH & Co. KG (Germany)0 个研究点目标入组 300 人开始时间: 2014年6月6日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • 1. Outpatients aged = 30 with unilateral or bilateral, chronic tinnitus (duration more than 3 months)
  • 2. Tinnitus in the context of hearing loss, noise or mental stress
  • 3. Tinnitus is the main complaint; other cochlear or vestibular symptoms may be present but less annoying
  • 4. Tinnitus stage according to Biesinger 2 or higher at baseline
  • 5. Written informed consent to participate in the clinical trial, to randomised treatment allocation and to data recording in accordance with applicable laws. Participants must be of age and they shall be able to realize the character, importance and consequences of the clinical trial and to align their volition with it.

排除标准

  • 1. Participation in another experimental drug trial at the same time or within the past 4 weeks before enrolment
  • 2. Any treatments for tinnitus taken currently or within 4 weeks before randomisation
  • 3. Acute or chronic otitis media or vestibular neuritis
  • 4. Drug-induced tinnitus
  • 5. Ongoing psychiatric disorder, such as major depression, generalized anxiety disorder, schizophrenia, etc
  • Of note: Symptoms of depression or anxiety or other behavioural or psychological symptoms at sub-syndromal level and not requiring treatment with psychotropic drugs are permitted.
  • 6. Severe cardiac or circulatory disorder
  • - severe (Canadian Cardiovascular Society stage IV) or unstable angina pectoris
  • - decompensated congestive heart failure (NYHA stage IV)
  • - uncontrolled hypertension with systolic blood pressure above 180 mmHg and/or diastolic blood pressure above 115 mmHg
  • - clinically significant cardiac arrhythmias (Lown classes IVb and V, bifascicular bundle
  • branch block).
  • 7. Severe renal or hepatic dysfunction (serum creatinine or serum ASAT, ALAT or gamma-GT above 3 times the upper limit of the reference range) or coagulation disorder
  • 8. Insulin-dependent diabetes mellitus
  • 9. Intake of drugs not permitted during participation in the study, in particular, insulin, psychoactive drugs, perfusion-enhancing drugs, cognition enhancing drugs or anti-cholinergic drugs (for details see section 6)
  • 10. Active malignant disease (exception: prostate cancer which does not require other than hormone treatment within the next 6 months)
  • 11. Known hypersensitivity to Ginkgo biloba extract or to excipients contained in the tablets
  • 12. Active peptic ulcer disease or any gastrointestinal disease with potential impairment of the absorption of orally applied drugs (e.g. Billroth I/II, Crohn's disease, ulcerative colitis, any kind of enterectomy)
  • 13. Female patients, who are pregnant, breast-feeding or of childbearing potential without safe contraception (hormonal contraception, oral or transdermal, and intra-uterine devices are considered sufficiently safe; child-bearing potential can be denied in case of postmenopausal state for at least 2 years, hysterectomy, bilateral tubal ligation or bilateral oophorectomy).

研究者

发起方
Dr. Willmar Schwabe GmbH & Co. KG (Germany)

相似试验